Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

